By Lecia Bushak |
December 14th, 2019
Last week, Biogen announced that its Alzheimer’s drug aducanumab was effective in combating Alzheimer’s disease after all, and that it would be reviving a trial cancelled earlier this year. However, questions still remain about what’s next for patients and doctors as the drug moves toward FDA approval.
Dr. Sharon Cohen, Medical Director and Principal Investigator at the Toronto Memory Program, shares her views on Biogen’s revived trial and the potential behind aducanumab.
Please advise status of drug in US and where we can learn more about it.
Hello Guy, please contact Biogen for information. ~ Thank you.
I have been diagnosed with Alzheimer’s and am interested in any new findings that can help slow its development.